CALL - SPRINTER OPEN END - VERTEX PHARMACEUTICALS | Real-time Boerse Frankfurt Warrants 05:32:10 18/06/2024 pm IST | ||
| 9.56 EUR | -4.11% |
|
| Current month | +30.33% | ||
| 1 month | +40.42% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about VERTEX PHARMACEUTICALS INCORPORATED
More news
| Date | Price | Change |
|---|---|---|
| 18/24/18 | 9.56 | -4.11% |
| 17/24/17 | 9.97 | -4.23% |
| 14/24/14 | 10.41 | +2.26% |
| 13/24/13 | 10.18 | +3.77% |
| 12/24/12 | 9.81 | -5.94% |
Real-time Boerse Frankfurt Warrants
Last update June 18, 2024 at 05:32 pm IST
More quotesStatic data
| Product type | Knock-Out without Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | VERTEX PHARMACEUTICALS INCORPORATED |
| Issuer | 
Vontobel
|
| WKN | VM6W8W |
| ISIN | DE000VM6W8W0 |
| Date issued | 12/12/2023 |
| Strike | 372.5 $ |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 0.06 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 10.78 € |
|---|---|
| Lowest since issue | 0.36 € |
| Spread | 0.04 € |
| Spread % | 0.41% |
Company Profile
Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases.
Net sales are distributed geographically as follows: the United States (61.2%), Europe (31.5%) and other (7.3%).
Sector
-
Ratings for Vertex Pharmaceuticals Incorporated
Trading Rating
Investor Rating
ESG Refinitiv
B+
Consensus: Vertex Pharmaceuticals Incorporated
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
31
Last Close Price
473.7
USD
Average target price
463.4
USD
Spread / Average Target
-2.17%
- Stock Market
- Certificates
- Certificat
